Medication info
Duo Well A Tablets 40/5/20 milligrams

Duo Well A Tablets 40/5/20 milligrams

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tablet
Manufacturer / importer
Yuhan Corporation
Appearance
Oval film-coated tablet in dark pink color
Packaging
30 tablets/box [6 tablets/PTP X 5]
Approval status
Active

MFDS item code 201805297 · Approved 2018.12.26 · Insurance code 642105350

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular risk
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take the tablet at the same time each day (e.g., in the morning). This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking the telmisartan/amlodipine combination together with rosuvastatin as separate products, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual components (telmisartan or amlodipine). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of telmisartan should not exceed 40 mg. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended starting dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 mg. Administration of the rosuvastatin 40 mg dose is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/5mg and rosuvastatin 20mg, rosuvastatin Cmax increased approximately 2.3-fold and AUC approximately 1.3-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, the potential risk due to the increase in rosuvastatin Cmax should be assessed, and patients should be monitored closely.

Ingredients

Manufacturer
Yuhan Corporation

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is used for patients with essential hypertension whose blood pressure is not adequately controlled even with the administration of a combination of Telmisartan and Amlodipine, and Rosuvastatin helps lower blood cholesterol levels in patients with hypercholesterolemia and dyslipidemia. In particular, Rosuvastatin has the effect of delaying the progression of atherosclerosis and reducing the risk of cardiovascular disease, and is used to reduce the risk of stroke, myocardial infarction, and recurrence after vascular revascularization in patients with high-sensitivity C-reactive protein levels or cardiovascular risk factors.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take the tablet at the same time each day (e.g., in the morning). This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking the telmisartan/amlodipine combination together with rosuvastatin as separate products, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual components (telmisartan or amlodipine). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of telmisartan should not exceed 40 mg. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended starting dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 mg. Administration of the rosuvastatin 40 mg dose is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/5mg and rosuvastatin 20mg, rosuvastatin Cmax increased approximately 2.3-fold and AUC approximately 1.3-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, the potential risk due to the increase in rosuvastatin Cmax should be assessed, and patients should be monitored closely.

Precautions

This medication should not be used by women who are pregnant. Special care is needed in early pregnancy, and if pregnancy is confirmed, the medication should be discontinued immediately. People who have allergies to the components of this medication or similar drugs, or have shown hypersensitivity reactions, should not take it. Patients with severely impaired liver or kidney function, and those with certain heart conditions should consult their doctor before using this medication. During the treatment, regular monitoring of liver function and muscle condition is important. If symptoms such as myalgia or muscle weakness appear, medical personnel should be notified immediately. Elderly patients or those with very low blood pressure, and patients with hyperkalemia need to be particularly cautious when taking this medication, and dosage adjustments should be made according to the doctor's instructions. This medication may interact with certain specific drugs when taken together, so it is essential to inform medical personnel of any medications currently being taken. It is best for breastfeeding women not to take this medication, and if it must be taken, breastfeeding should be discontinued. Safety and efficacy in children and adolescents has not been thoroughly confirmed and is not recommended. In case of overdose, symptoms such as hypotension, dizziness, and heart problems may occur, so if abnormal symptoms arise, medical personnel should be contacted right away. Keep this medication out of reach of children, and it is safer not to transfer it to another container when storing.

Side effects

Viral upper respiratory tract infection, conjunctivitis, peripheral edema, chest discomfort, dizziness, abdominal pain, duodenitis, arthralgia, herniated disc, spinal stenosis, tinnitus, increased ALT, increased AST, increased ALP, increased γ-GTP, chronic gastritis, hiatal hernia, musculoskeletal pain, neck pain, nasopharyngitis, upper abdominal discomfort, upper abdominal pain, positional dizziness, dysuria, rhinitis, pharyngeal discomfort, pulmonary disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorder, atherosclerosis, urinary frequency, tinnitus, hearing loss, halitosis, fatty liver, headache, edema, flushing, palpitations, fatigue, nausea, drowsiness, arrhythmia, bradycardia, thoracic pain, peripheral ischemia, syncope, orthostatic hypotension, vasculitis, peripheral neuropathy, tremors, vertigo, loss of appetite, constipation, dyspepsia, dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasia, allergic reaction, burning sensation, malaise, pain, stiffness, weight gain, weight loss, erectile dysfunction, insomnia, neuroticism, depression, abnormal dreams, anxiety, depersonalization, dyspnea, nosebleed, angioedema, erythema multiforme, pruritus, rash, erythematous rash, papular rash, double vision, ocular pain, otic pain, frequent urination, urination disorders, nocturia, dry mouth, increased sweating, hyperglycemia, thirst, leukopenia, purpura, thrombocytopenia, angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, angioedema, pruritus, hypersensitivity reaction, increased sweating, erythema, thoracic pain, atrial fibrillation, congestive heart failure, myocardial infarction, increased blood pressure, worsening hypertension, hypotension, hyperkalemia, hypoglycemia, syncope, dyspepsia, diarrhea, urinary tract infection, erectile dysfunction, low back pain, muscle cramps, bradycardia, eosinophilia, thrombocytopenia, increased uric acid, liver dysfunction, liver disease, acute renal failure, anemia, increased CPK, anaphylactic reaction, tendon pain, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, eosinophilia with systemic symptoms drug reaction syndrome, lupus-like syndrome, muscle rupture, memory loss, peripheral neuropathy, cough, dyspnea, diarrhea, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, depression, sleep disorders, interstitial lung disease, edema, acute renal failure, oliguria, elevated serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to light, so it should be stored in a container that protects it from light. Additionally, it is advisable to store the medication at room temperature between 1 degree and 30 degrees Celsius. This storage method helps maintain the medication's efficacy and safety.

Appearance and packaging

Appearance

Oval film-coated tablet in dark pink color

Package unit

30 tablets/box [6 tablets/PTP X 5]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.